Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.48 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1602223 | 0.88 | TSHR (0.47) | LTA4HCYP2D6PLA2G4BTSHRSMN1; SMN2 | |
| SCHEMBL1603336 | 0.86 | S1PR1 (0.46) | CYP3A4CA1CA2SMN1; SMN2MAPK1 | |
| SCHEMBL17400969 | 0.86 | NQO1 (0.61) | LTA4HCA12CA1CA2TSHR | |
| SCHEMBL8224347 | 0.85 | LTA4H (0.48) | LTA4HNR5A1CYP3A4CYP2D6PLA2G4B | |
| SCHEMBL16519363 | 0.84 | NQO1 (0.46) | LTA4HCYP3A4CYP2D6TSHRKDM4E | |
| SCHEMBL5779539 | 0.82 | USP2 (0.45) | CYP3A4CYP2D6TSHRSMN1; SMN2KDM4E | |
| SCHEMBL1951190 | 0.82 | CYP2C9 (0.50) | CA12CA1CA2TSHRCA7 | |
| SCHEMBL8227407 | 0.81 | NR5A1 (0.53) | LTA4HNR5A1PLA2G4BTSHRSLC2A1 | |
| SCHEMBL8223217 | 0.81 | LTA4H (0.42) | LTA4HNR5A1CYP3A4CYP2D6CA12 | |
| SCHEMBL20539545 | 0.81 | APP (0.44) | LTA4HTSHRNQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364976-B1 | S1P receptor modulating compounds and use thereof | EPIX PHARM INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2364976-A1 | S1P receptor modulating compounds and use thereof | EPIX Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110059945-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059945-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-7855193-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855193-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2008-03-13 | — | — | US | disclosed |
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2008-03-13 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2007109334-A2 | SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | disclosed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | disclosed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | disclosed |
| WO-2007061458-A2 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | LTA4H 203/4885NR5A1 274/4885CYP3A4 2766/4885 |
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | LTA4H 203/4885NR5A1 274/4885CYP3A4 2766/4885 |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR5, S1PR2 | LTA4H 203/4885NR5A1 274/4885CYP3A4 2766/4885 |
| US-20110059945-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR5, S1PR2 | LTA4H 203/4885NR5A1 274/4885CYP3A4 2766/4885 |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | LTA4H 203/4885NR5A1 274/4885CYP3A4 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.